IRA Part III: Medicare’s Maximum Fair Prices for the First 10 Negotiated Drugs and Anticipated Cost Savings

October 22, 2024

Back to all webinars

Open to all ISPOR Members and Non-members


Title: IRA Part III: Medicare’s Maximum Fair Prices for the First 10 Negotiated Drugs and Anticipated Cost Savings 

Tuesday, October 22, 2024
10:00AM EDT | 2:00PM UTC | 4:00PM CEST

Click here for time zone conversion

Register Now

 

Description

Drs. Inma Hernandez and Sean D. Sullivan will compare the recently published Medicare Maximum Fair Prices (MFPs) with net prices before negotiation to discuss the potential magnitude of savings achieved by negotiation. Drs. John O’Brien of the National Pharmaceutical Council and Greg Daniel of Eli Lilly will provide additional context for the MFPs and the estimated cost savings projections. This session will be highly relevant for professionals and researchers in market access, pricing, and HEOR. 

The webinar will begin with an explanation of the MFPs and how CMS likely estimated the initial and final price offers. Speakers and panelists will discuss the impact the published MFPs will have on the Medicare Part D prescription drug budget and potential spillover effects into other federal and private sector markets. 

Additional Resources

Learning Objectives

  • Compare negotiated prices to net prices and other price benchmarks faced by payers before negotiation.
  • Identify approaches to estimating the main sources of savings associated from the first 10 drugs selected for negotiation.
  • Discuss the potential role of comparative effectiveness research on the derivation of negotiated prices.

 

Speakers:

Inmaculada (Inma) Hernandez, PhD, Professor, Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, USA

Sean D. Sullivan, PhD, Professor, UW CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA

John M. O’Brien, PharmD, MPH, President and CEO, National Pharmaceutical Council, Washington, DC, USA

Greg Daniel, PhD, MPH, Vice President, Global Public Policy, Eli Lilly and Company, Washington, DC, USA

Brought to you by: ISPOR


Please note:
 On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar.

Reservations are on a first-come, first-served basis.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×